SARTORIUS (UNSP.ADS)/1/5

Research SARTORIUS (UNSP.ADS)/1/5 (SRT0) on Bullrun: valuation model: 38.4% overvalued, market cap EUR 14.09B, P/E 86.8, dividend yield 0.4%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerSRT0
• ExchangeF
• CountryGermany
• SectorHealthcare
• IndustryMedical Instruments & Supplies
• CurrencyEUR
• Valuation signal38.4% overvalued
• Market capEUR 14.09B
• P/E86.8
• Dividend yield0.4%
• Financial periodQ1 2026
• RevenueEUR 899.10M
• Net incomeEUR 56.20M
• Free cash flowEUR 111.20M
• Gross margin46.1%

Valuation Snapshot

Bullrun's latest valuation model marks SARTORIUS (UNSP.ADS)/1/5 as 38.4% overvalued; latest market cap is EUR 14.09B; P/E is 86.8; dividend yield is 0.4%.

About SARTORIUS (UNSP.ADS)/1/5

Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems;

Frequently asked questions

Is SARTORIUS (UNSP.ADS)/1/5 overvalued or undervalued?

Bullrun's valuation model currently marks SARTORIUS (UNSP.ADS)/1/5 as 38.4% overvalued.

What is SARTORIUS (UNSP.ADS)/1/5's market cap?

SARTORIUS (UNSP.ADS)/1/5's market capitalization is EUR 14.09B.

What is SARTORIUS (UNSP.ADS)/1/5's P/E ratio?

SARTORIUS (UNSP.ADS)/1/5's price-to-earnings (P/E) ratio is 86.8.

Does SARTORIUS (UNSP.ADS)/1/5 pay a dividend?

SARTORIUS (UNSP.ADS)/1/5 has a dividend yield of 0.4%.

What does SARTORIUS (UNSP.ADS)/1/5 do?

Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and...